Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Athenex Inc (ATNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Athenex Announces Positive Recommendations from the Drug Safety Monitoring Board to Continue the Oraxol Phase III Program

Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 17.13 (+0.29%)
Athenex, Inc. Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis

Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 17.13 (+0.29%)
Athenex, Inc. Added to Russell 2000(R) and Russell 3000(R) Indexes

Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that it has...

ATNX : 17.13 (+0.29%)
CORRECTING and REPLACING: Athenex, Inc.

In a release issued earlier today by Athenex, Inc. (Nasdaq:ATNX), please note that the headline and dateline have been updated. The corrected release follows:

ATNX : 17.13 (+0.29%)
ContraVir Pharmaceuticals Receives HBV IND Approval for Tenofovir Exalidex (TXL(TM)) in the United States

Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that it has...

ATNX : 17.13 (+0.29%)
CTRV : 0.73 (-2.03%)
Athenex Pharmaceutical Division and SunGen Pharma Announce Terbutaline Sulfate Injection Product Launch

Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the launch...

ATNX : 17.13 (+0.29%)
Athenex, Inc. Announces Second Quarter 2017 Results

-- Received Chinese FDA approval to begin clinical trials of KX-02 Tablet for Glioblastoma

ATNX : 17.13 (+0.29%)
Rand Capital Announces Second Quarter 2017 Results

BUFFALO, NY--(Marketwired - August 07, 2017) -

ATNX : 17.13 (+0.29%)
RAND : 2.96 (+1.37%)
Rand Capital Announces Second Quarter 2017 Results

BUFFALO, NY--(Marketwired - August 07, 2017) -

ATNX : 17.13 (+0.29%)
RAND : 2.96 (+1.37%)
Athenex Announces Recent Product Launches in Commercial Business

Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced recent product...

ATNX : 17.13 (+0.29%)
Athenex, Inc. to Report Second Quarter 2017 Earnings Results on August 14, 2017

Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that it will...

ATNX : 17.13 (+0.29%)
IPO Market Back On Track: ETFs to Tap

After several lackluster quarters, the U.S. IPO market gained momentum in the second quarter of 2017.

BHVN : 31.67 (-3.21%)
APPN : 23.11 (+0.48%)
ATNX : 17.13 (+0.29%)
SGH : 31.04 (-2.33%)
KHC : 76.71 (+0.31%)
IPO : 27.82 (+2.15%)
ABBV : 96.10 (-0.39%)
FPX : 65.91 (+0.92%)
ATUS : 26.02 (+1.96%)
IPO Market Back On Track: ETFs to Tap

After several lackluster quarters, the U.S. IPO market gained momentum in the second quarter of 2017.

BHVN : 31.67 (-3.21%)
APPN : 23.11 (+0.48%)
ATNX : 17.13 (+0.29%)
SGH : 31.04 (-2.33%)
KHC : 76.71 (+0.31%)
IPO : 27.82 (+2.15%)
ABBV : 96.10 (-0.39%)
FPX : 65.91 (+0.92%)
ATUS : 26.02 (+1.96%)
Athenex, Inc. Announces Closing of Initial Public Offering and Full-Exercise of Over-Allotment Option

Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the closing...

ATNX : 17.13 (+0.29%)
DB : 16.98 (+0.65%)
Nasdaq Welcomes Athenex, Inc. (Nasdaq: ATNX) to The Nasdaq Stock Market

Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, visited the Nasdaq MarketSite...

NDAQ : 72.92 (-0.03%)
ATNX : 17.13 (+0.29%)
Athenex, Inc. Announces Pricing of Initial Public Offering

Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the pricing...

ATNX : 17.13 (+0.29%)
Athenex, Inc. (Nasdaq: ATNX) to Ring The Nasdaq Stock Market Closing Bell in Celebration of Its IPO

What:

NDAQ : 72.92 (-0.03%)
ATNX : 17.13 (+0.29%)
Athenex and Its Partner, Guangzhou Xiangxue Pharmaceutical, Announced Chinese FDA IND Approval to Begin Clinical Trials of KX-02 Tablet for Glioblastoma

Athenex, Inc., Buffalo, NY, a global specialty oncology pharmaceutical company focusing on the development and commercialization of next generation therapies for cancers and supportive therapies, announced...

ATNX : 17.13 (+0.29%)

Van Meerten Stock Picks

My 5 Favorite NASDAQ 100 Stocks
This morning I wanted to find the 5 best NASDAQ 100 stocks that had the highest return in the past year, had consistent price appreciation and still looked like they had room to go.
AMAT +0.76 , NVDA -0.90 , ADSK +1.52 , MU +0.19 , LRCX +4.36
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 +0.21%) this morning are up +0.23% at a new record high on optimism that the Trump administration will be able to enact its tax reform plans after the Senate adopted a fiscal 2018 budget... Read More

Chart of the Day

Chart of the Day

LimeLight Networks (LLNW) is the Barchart Chart of the Day.  The Internet company has a Trend Spotter buy signal, a Weighted Alpha of 18.33+ and gained 149.71% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures ended Friday with most contracts 3 1/2 to 4 1/2 cents lower. The USDA announced private export sales of 125,000 MT of corn to Unknown Destinations, with an additional 120,000 MT to Spain for 17/18 delivery through their daily reporting s...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart